Idiopathic Parkinson's Disease

Neurology
17
Pipeline Programs
6
Companies
19
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
10
4
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

UP
NEUPROApproved
rotigotine
UCB Pharma
Nonergot Dopamine Agonist [EPC]transdermal2007
U
SAFINAMIDEApproved
safinamide
Unknown Company
oral

Competitive Landscape

6 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
7 programs
4
2
RotigotinePhase 41 trial
RotigotinePhase 41 trial
RotigotinePhase 31 trial
RotigotinePhase 31 trial
RotigotinePhase 31 trial
+2 more programs
Active Trials
NCT01330290Completed148Est. Aug 2012
NCT00505687Completed186Est. Dec 2008
NCT01646268Completed249Est. May 2014
+4 more trials
Newron Pharmaceuticals
5 programs
1
4
SafinamidePhase 31 trial
SafinamidePhase 31 trial
Safinamide, MAO-B inhibitorPhase 31 trial
Safinimide 50-100 mg/dayPhase 31 trial
Safinamide + LevodopaPhase 1/21 trial
Active Trials
NCT01026428Completed
NCT00643045CompletedEst. Jul 2007
NCT00605683CompletedEst. Mar 2012
+2 more trials
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
2 programs
2
Istradefylline 20 mg or 40 mgPhase 31 trial
Istradefylline 40 mgPhase 31 trial
Active Trials
NCT02610231Completed239Est. Dec 2017
NCT01968031Completed613Est. Oct 2016
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
LiaterminPhase 12 trials
Safety observationN/A1 trial
Active Trials
NCT00148369Completed31Est. Sep 2007
NCT00111982Completed34Est. Feb 2006
NCT00115427Completed
Voyager Therapeutics
1 program
1
VY-AADC01Phase 11 trial
Active Trials
NCT03065192CompletedEst. Aug 2021
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
pramipexoleN/A1 trial
Active Trials
NCT01470859Completed30Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaRotigotine
UCB PharmaRotigotine
Kyowa Hakko KirinIstradefylline 20 mg or 40 mg
Kyowa Hakko KirinIstradefylline 40 mg
UCB PharmaRotigotine
UCB PharmaRotigotine
Newron PharmaceuticalsSafinamide, MAO-B inhibitor
Newron PharmaceuticalsSafinimide 50-100 mg/day
Newron PharmaceuticalsSafinamide
UCB PharmaRotigotine
Newron PharmaceuticalsSafinamide
UCB PharmaRotigotine
Newron PharmaceuticalsSafinamide + Levodopa
AmgenLiatermin
Voyager TherapeuticsVY-AADC01

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 2,436 patients across 19 trials

NCT01782222UCB PharmaRotigotine

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Start: Feb 2013Est. completion: Mar 2014122 patients
Phase 4Completed
NCT01523301UCB PharmaRotigotine

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Start: Apr 2012Est. completion: Oct 2014380 patients
Phase 4Completed
NCT02610231Kyowa Hakko KirinIstradefylline 20 mg or 40 mg

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Start: Dec 2015Est. completion: Dec 2017239 patients
Phase 3Completed
NCT01968031Kyowa Hakko KirinIstradefylline 40 mg

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Start: Oct 2013Est. completion: Oct 2016613 patients
Phase 3Completed
NCT01646268UCB PharmaRotigotine

Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

Start: Jul 2012Est. completion: May 2014249 patients
Phase 3Completed
NCT01646255UCB PharmaRotigotine

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

Start: Jul 2012Est. completion: Oct 2014346 patients
Phase 3Completed
NCT01028586Newron PharmaceuticalsSafinamide, MAO-B inhibitor

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

Start: Oct 2009
Phase 3Terminated
NCT00627640Newron PharmaceuticalsSafinimide 50-100 mg/day

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Start: Feb 2009Est. completion: Mar 2012
Phase 3Completed
NCT00605683Newron PharmaceuticalsSafinamide

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

Start: Nov 2007Est. completion: Mar 2012
Phase 3Completed
NCT00505687UCB PharmaRotigotine

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Start: Feb 2005Est. completion: Dec 2008186 patients
Phase 3Completed
NCT00643045Newron PharmaceuticalsSafinamide

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Start: Dec 2004Est. completion: Jul 2007
Phase 3Completed
NCT00243945UCB PharmaRotigotine

A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease

Start: Dec 2004Est. completion: Jul 200558 patients
Phase 3Completed
NCT01026428Newron PharmaceuticalsSafinamide + Levodopa

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Start: Sep 2009
Phase 1/2Completed
NCT00111982AmgenLiatermin

Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin

Start: Dec 2003Est. completion: Feb 200634 patients
Phase 1/2Completed
NCT03065192Voyager TherapeuticsVY-AADC01

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Start: May 2017Est. completion: Aug 2021
Phase 1Completed
NCT00115427AmgenLiatermin

Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Start: Mar 2003
Phase 1Completed
NCT01470859Boehringer Ingelheimpramipexole

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

Start: Dec 2011Est. completion: Aug 201430 patients
N/ACompleted
NCT01330290UCB PharmaNeupro®

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

Start: Mar 2011Est. completion: Aug 2012148 patients
N/ACompleted
NCT00148369AmgenSafety observation

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

Start: Jun 2005Est. completion: Sep 200731 patients
N/ACompleted

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
4h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
4h ago

Director of Medical Affairs

CoMind
Miami, FL
4h ago

Director of Finance

CoMind
London, UK
4h ago

Electronics Engineering Manager

CoMind
London, UK
4h ago

Director of Information Technology

Zavation Medical Products
5h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)